Intermountain Heart Institute Research Update. Brent Muhlestein, MD Co-Director of Cardiology Research Intermountain Heart Institute

Size: px
Start display at page:

Download "Intermountain Heart Institute Research Update. Brent Muhlestein, MD Co-Director of Cardiology Research Intermountain Heart Institute"

Transcription

1 Intermountain Heart Institute Research Update Brent Muhlestein, MD Co-Director of Cardiology Research Intermountain Heart Institute

2 Disclosures I will not discuss off label use or investigation use in my presentation I have no financial relationships to disclose

3

4

5

6

7

8 Highlights of Intermountain Heart Institute Program Development 2016 Recruitment and hiring of Kirk Ute Knowlton, MD as director of cardiology research BS in Chemistry from Brigham Young University MD from University of Utah Internal medicine residency at Duke University Cardiology Fellowship at University of California San Diego Highly published basic scientist studying myocarditis Clinical expert in pulmonary hypertension and pulmonary thromboembolic disease Chief of Cardiology at UCSD for over 10 years. Was acting Chairman of Internal Medicine at UCSD upon recruitment

9 Highlights of Intermountain Heart Institute Program Development continued Expansion of our research team to handle more investigator initiated studies. Development of an enhanced and formalized quality and compliance organization. Expanded interaction with industry in regards to collaborative investigator initiated studies Bristol Myers Squibb Corporation Medicure Corporation Medicines Company Enhanced Interaction with Philanthropy Dell Loy Hansen Cardiovascular Research Foundation - $1,000,000 Oakland Family Foundation Bingham Family Foundation

10 Three Published Research Studies from this Past Year Highlighted

11

12 Standard 12 Lead ECG Machine

13 Smart Phone 12 Lead ECG Machine

14 Standard 12 Lead ECG

15 Smart Phone 12 Lead ECG

16

17 ST LEUIS Multicenter Trial Aim: Can STEMI be diagnosed as accurately with a smart phone ECG machine as with a standard 12 lead ECG machine Plan to enroll 300 patients more than half already enrolled 200 chest pain patients 100 STEMI activation patients Multiple Sites participating Supervised by Intermountain Heart Institute Intermountain Heart Institute, Salt Lake City, UT Duke University, Durham, NC Mayo Clinic, Rochester, MN Integris Heart Hospital, Oklahoma City, OK Erlanger Institute for Clinical Research, Chattanooga, TN Argentina Heart Institute, Buenos Aires, Argentina

18

19 Survival by Quartile Group of Endogenous Testosterone Concentrations (1 is lowest, 4 is highest)

20 Low testosterone in men increases their risk of death.

21 So Having Low Testosterone is Bad. Does Replacing it Help?

22

23

24 May 4, 2015 FDA Announcement

25 Can the Intermountain Heart Institute Contribute Valuable Information to Help Address this Question?

26 Methods 4,736 males with initially low testosterone (T) levels and available follow-up T levels were included and followed for more than 3 years. The primary outcome was a composite of death (D), nonfatal myocardial infarction and stroke (MACE). Multivariable adjusted hazard ratios (HRs) obtained between three groups: Persistent low T (<212 ng/dl, n=801) Normal T ( ng/dl, n=2,241) High T (>742 ng/dl, n=1,694)

27

28

29 Conclusions In a large general healthcare population, TRT in men with low T was associated with reduced MACE and D over 3 years compared to no or ineffective TRT. However, absence of a clear benefit for CVspecific MACE and a nominal increase in stroke with high follow-up T suggest a conservative approach to TRT for cardiovascular protection. We are pursuing more research into this important topic.

30

31

32

33 STEMI

34 Conclusion Elevated fine particulate matter air pollution exposures contribute to triggering acute coronary events, especially ST segment elevation myocardial infarction.

35 Summary Thanks to all the support from many persons within Intermountain Healthcare, cardiovascular research at the Intermountain Heart Institute is well and thriving. Research performed here has a significant impact far beyond our own borders. I believe this research contributes significantly to the extraordinary cardiovascular care provided by the Intermountain Heart Institute.

36 Thank you!

ACCP Cardiology PRN Journal Club

ACCP Cardiology PRN Journal Club ACCP Cardiology PRN Journal Club Announcements Next journal club Thursday, Dec. 14 th at 3:00 PM EST PACIFY Trial Effects of IV Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients

More information

Jeffrey L Anderson, MD, MACP, FACC, FAHA. Intermountain Medical Center, Murray, Utah University of Utah School of Medicine, Salt Lake City, UT

Jeffrey L Anderson, MD, MACP, FACC, FAHA. Intermountain Medical Center, Murray, Utah University of Utah School of Medicine, Salt Lake City, UT Tegaserod: are the data sufficiently compelling for a class effect that CV safety outcomes should be required for all 5HT-4 agonists for severe constipation? Jeffrey L Anderson, MD, MACP, FACC, FAHA Intermountain

More information

Pragmatic Trial Design to Study Health Policy Interventions: Lessons Learned from ARTEMIS Tracy Y. Wang, MD, MHS, MSc, FACC, FAHA

Pragmatic Trial Design to Study Health Policy Interventions: Lessons Learned from ARTEMIS Tracy Y. Wang, MD, MHS, MSc, FACC, FAHA Pragmatic Trial Design to Study Health Policy Interventions: Lessons Learned from ARTEMIS Tracy Y. Wang, MD, MHS, MSc, FACC, FAHA Associate Professor of Medicine, Duke University Director of Health Services

More information

The Data Collection on Adverse events of Anti-HIV Drugs

The Data Collection on Adverse events of Anti-HIV Drugs Dias 1 The Data Collection on Adverse events of Anti-HIV Drugs Ole Kirk, University of Copenhagen Denmark Dias 2 The Need for D:A:D February 1999, EMEA/Committee for Medicinal Products for Human Use (CHMP)

More information

- May Help Increase Appropriate Early Use in Acute Coronary Syndrome Patients -

- May Help Increase Appropriate Early Use in Acute Coronary Syndrome Patients - MEDIA INVESTORS Ken Dominski John Elicker Bristol-Myers Squibb Bristol-Myers Squibb 609-252-5251 212-546-3775 ken.dominski@bms.com john.elicker@bms.com Amy Ba Felix Lauscher sanofi-aventis sanofi-aventis

More information

Rebuilding and Reinvigorating Cardiac Rehabilitation in 2018

Rebuilding and Reinvigorating Cardiac Rehabilitation in 2018 Rebuilding and Reinvigorating Cardiac Rehabilitation in 2018 Pam R. Taub MD, FACC Director of Step Family Cardiac Wellness and Rehabilitation Center Associate Professor of Medicine UC San Diego Health

More information

Simple, Rapid Antiplatelet Therapy Response Assessment

Simple, Rapid Antiplatelet Therapy Response Assessment Simple, Rapid Antiplatelet Therapy Response Assessment Acute Care Diagnostics Antiplatelet therapy. Is it working? At least 1 in 3 patients on antiplatelet therapies do not receive the intended physiological

More information

Value of Cardiac Rehabilitation for Improving Patient Outcomes

Value of Cardiac Rehabilitation for Improving Patient Outcomes Value of Cardiac Rehabilitation for Improving Patient Outcomes Pam R. Taub MD, FACC Director of Step Family Cardiac Wellness and Rehabilitation Center Associate Professor of Medicine UC San Diego Health

More information

2018 Computed Tomography

2018 Computed Tomography Release Date: April 15, 17.75 AMA PRA Category 1 Credit(s) TM About This CME Teaching Activity This CME activity is a practical, yet clinically relevant review of CT imaging with an emphasis on the latest

More information

VCU HEALTH SYSTEM EMERGENCY DEPARTMENT GUIDELINE

VCU HEALTH SYSTEM EMERGENCY DEPARTMENT GUIDELINE VCU HEALTH SYSTEM EMERGENCY DEPARTMENT GUIDELINE SUBJECT: Care of the Chest Pain Patient in the Emergency Department FILE SECTION: VCUHS/ED Section: Please note: Clinical Practice Guideline Evidence-based

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease

The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,

More information

Modern Lipid Management:

Modern Lipid Management: Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)

More information

Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.

Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai. Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,

More information

Curriculum Vitae. PERSONAL DATA Name: Harriet W. Hopf Birth Place: Madison, WI Citizenship: United States

Curriculum Vitae. PERSONAL DATA Name: Harriet W. Hopf Birth Place: Madison, WI Citizenship: United States Curriculum Vitae PERSONAL DATA Name: Harriet W. Hopf Birth Place: Madison, WI Citizenship: United States EDUCATION Years Degree Institution (Area of Study) 1978-1982 B.A. Yale University (Biology) New

More information

Primary Care Updates ACP conference 2015

Primary Care Updates ACP conference 2015 Primary Care Updates ACP conference 2015 Richard Rose, MD FACP Assistant Professor University of Utah Department of General Internal Medicine VAMC - Internal Medicine Nothing to disclose Conflicts of interest

More information

Organizational, or Other Financial Benefit None None None None None None. None None None None None None

Organizational, or Other Financial Benefit None None None None None None. None None None None None None Comprehensive Relationships With Industry and Other Entities AHA/ACC 2017 Update of ST-Elevation Myocardial Infarction and Non ST-Elevation Myocardial Infarction Measures Committee Jneid Hani, Chair Baylor

More information

Preliminary Programme

Preliminary Programme Preliminary Programme The scientific programme comprises various styles of presentations and sessions, each offering a unique opportunity to amass new and important scientific information. Optimal management

More information

HIP ATTACK Trial: Can we improve outcomes after a hip fracture with accelerated surgery? PJ Devereaux, MD, PhD

HIP ATTACK Trial: Can we improve outcomes after a hip fracture with accelerated surgery? PJ Devereaux, MD, PhD HIP ATTACK Trial: Can we improve outcomes after a hip fracture with accelerated surgery? PJ Devereaux, MD, PhD Disclosure Member of research group with policy of not accepting honorariums or other payments

More information

Debate Continues on Ticagrelor in PLATO

Debate Continues on Ticagrelor in PLATO Debate Continues on Ticagrelor in PLATO www.medscape.com Lisa Nainggolan March 14, 2011 March 11, 2011 (Durham, North Carolina) AstraZeneca should conduct a second trial with its investigational antiplatelet

More information

How agressively should we treat asymptomatic patients with Brugada syndrome. Josep Brugada Medical Director Hospital Clínic, University of Barcelona

How agressively should we treat asymptomatic patients with Brugada syndrome. Josep Brugada Medical Director Hospital Clínic, University of Barcelona How agressively should we treat asymptomatic patients with Brugada syndrome Josep Brugada Medical Director Hospital Clínic, University of Barcelona The ECG in Brugada syndrome - Prolonged PR - RBBB - ST

More information

Cardiovascular Medicine at Reading Hospital: Update May 2018

Cardiovascular Medicine at Reading Hospital: Update May 2018 Cardiovascular Medicine at Reading Hospital: Update May 2018 Eric Elgin, MD, FSCAI, FACC Cardiology Section Chief Department of Medicine Reading Hospital Tower Health System Nothing to disclose Disclosures

More information

Estrogens vs Testosterone for cardiovascular health and longevity

Estrogens vs Testosterone for cardiovascular health and longevity Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in

More information

ARISTOTLE Demonstrated that ELIQUIS is the First Oral Anticoagulant to Significantly Reduce All-Cause Death

ARISTOTLE Demonstrated that ELIQUIS is the First Oral Anticoagulant to Significantly Reduce All-Cause Death ELIQUIS (apixaban) was Superior to Warfarin for the Reduction of Stroke or Systemic Embolism with Significantly Less Major Bleeding in Patients with Atrial Fibrillation in Phase 3 ARISTOTLE Trial ARISTOTLE

More information

J. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018

J. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018 ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events): A Study to Assess the Efficacy and Safety of Aspirin in Patients at Moderate Risk of Cardiovascular Disease J. Michael Gaziano, M.D., M.P.H.

More information

Where Do We Stand? Unraveling the FDA Regulatory Pathway for Diabetes and Obesity Drug Approval. Alexander Fleming, MD

Where Do We Stand? Unraveling the FDA Regulatory Pathway for Diabetes and Obesity Drug Approval. Alexander Fleming, MD Where Do We Stand? Unraveling the FDA Regulatory Pathway for Diabetes and Obesity Drug Approval Alexander Fleming, MD 1 Presenter Disclosure Alexander Fleming, M.D. Board Member/Advisory Panel/Consultant:

More information

No Other Company Discloses Higher Transplant Survival Rate. Infusions For Emerging Treatments. Date of Use. Recipient Age (yrs)

No Other Company Discloses Higher Transplant Survival Rate. Infusions For Emerging Treatments. Date of Use. Recipient Age (yrs) Units Used In Transplants/Infusions No Other Company Discloses Higher Transplant Survival Rate Family Banking Provides Exclusive Access To Emerging Treatments With Your Own Cells 175 85% Type 1 Diabetes

More information

Cindy L. Grines MD FACC FSCAI

Cindy L. Grines MD FACC FSCAI Cindy L. Grines MD FACC FSCAI Hofstra Northwell School of Medicine Chair, Cardiology Academic Chief of Cardiology, Northwell Health North Shore University Hospital, Manhasset NY Multivessel Disease in

More information

Myocardial Injury after Noncardiac Surgery (MINS): What is it and what can we do to help patients suffering this event? PJ Devereaux, MD, PhD

Myocardial Injury after Noncardiac Surgery (MINS): What is it and what can we do to help patients suffering this event? PJ Devereaux, MD, PhD Myocardial Injury after Noncardiac Surgery (MINS): What is it and what can we do to help patients suffering this event? PJ Devereaux, MD, PhD Disclosure Member of research group with policy of not accepting

More information

Disclosures The PREVENT IV Trial was supported by Corgentech and Bristol-Myers Squibb

Disclosures The PREVENT IV Trial was supported by Corgentech and Bristol-Myers Squibb Saphenous Vein Grafts with Multiple Versus Single Distal Targets in Patients Undergoing Coronary Artery Bypass Surgery: One-Year Graft Failure and Five-Year Outcomes from the Project of Ex-vivo Vein Graft

More information

Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the Secondary Prevention of Myo

Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the Secondary Prevention of Myo Xarelto (Rivaroxaban) Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the Secondary Prevention of Myocardial Infarction and Death in Patients with Coronary or Peripheral Artery

More information

UPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME. DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18

UPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME. DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18 UPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18 INTRODUCTION The clinical entities that comprise acute coronary syndromes (ACS)-ST-segment

More information

Vascular Protection: Preventing Thrombotic Complications of VTE and PAD

Vascular Protection: Preventing Thrombotic Complications of VTE and PAD Vascular Protection: Preventing Thrombotic Complications of VTE and PAD Thursday, October 11, 2018, 2:00pm ET Guest Speakers: Geoff Barnes, MD Scott Damrauer, MD Moderators: Tracy Minichiello, MD; Sara

More information

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National

More information

INDIVIDUALIZED MEDICINE

INDIVIDUALIZED MEDICINE CENTER FOR INDIVIDUALIZED MEDICINE Clopidogrel Pharmacogenetics Can We Impact Clinical Practice? Michael E. Farkouh, MD, MSc Peter Munk Cardiac Centre University of Toronto Naveen Pereira MD Mayo Clinic

More information

REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO

REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO REFERRAL HOSPITAL The Importance of Door In Door Out Time DIDO Jean Skonhovd,RN,BSN,MSAS Emergency Department Director Avera Heart Hospital of South Dakota Time to Treatment is critical for STEMI patients

More information

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban

More information

Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists

Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict

More information

Air Quality: What an internist needs to know

Air Quality: What an internist needs to know Air Quality: What an internist needs to know Robert Paine, M.D. Pulmonary and Critical Care Medicine University of Utah School of Medicine Program for Air Quality, Health and Society February, 2017 October

More information

New insights in stent thrombosis: Platelet function monitoring. Franz-Josef Neumann Herz-Zentrum Bad Krozingen

New insights in stent thrombosis: Platelet function monitoring. Franz-Josef Neumann Herz-Zentrum Bad Krozingen New insights in stent thrombosis: Platelet function monitoring Franz-Josef Neumann Herz-Zentrum Bad Krozingen New insights in stent thrombosis: Platelet function monitoring Variability of residual platelet

More information

Cover Page. The handle holds various files of this Leiden University dissertation

Cover Page. The handle  holds various files of this Leiden University dissertation Cover Page The handle http://hdl.handle.net/1887/21543 holds various files of this Leiden University dissertation Author: Dharma, Surya Title: Perspectives in the treatment of cardiovascular disease :

More information

Relationship between Center Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results from the ROCKET AF Trial

Relationship between Center Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results from the ROCKET AF Trial Relationship between Center Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results from the ROCKET AF Trial Jonathan P. Piccini, Frank Harrell, Yulia Lokhnygina,

More information

MINNEAPOLIS September 12, 2012 Medtronic, Inc. (NYSE: MDT) today announced findings

MINNEAPOLIS September 12, 2012 Medtronic, Inc. (NYSE: MDT) today announced findings NEWS RELEASE Contacts: Wendy Dougherty Jeff Warren Public Relations Investor Relations 707-541-3004 763-505-2696 FOR IMMEDIATE RELEASE HEALTH-ECONOMIC ANALYSIS SUGGESTS MEDTRONIC SYMPLICITY RENAL DENERVATION

More information

Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy

Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy Learning Objectives Learn to recognize the high risk patient Discuss effective management of a high risk NSTEMI patient Review CCS

More information

DR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, "G. PAPANIKOLAOU" GH, THESSALONIKI

DR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, G. PAPANIKOLAOU GH, THESSALONIKI The Impact of AF on Natural History of CAD DR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, "G. PAPANIKOLAOU" GH, THESSALONIKI CAD MOST COMMON CARDIOVASCULAR DISEASE MOST COMMON CAUSE OF DEATH

More information

Bayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media

Bayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the

More information

Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study

Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study Hidenori Arai 1, Yoshihiro Kokubo 2, Makoto Watanabe 2, Tatsuya Sawamura 3, Tomonori

More information

SYNOPSIS. Clinical Study Report CN138002: Addendum 1. Individual Study Table Referring to the Dossier

SYNOPSIS. Clinical Study Report CN138002: Addendum 1. Individual Study Table Referring to the Dossier Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abilify Name of Active Ingredient: aripiprazole Individual Study Table Referring to the Dossier (For National Authority Use Only)

More information

Data Collection on Adverse Events of Anti-HIV Drugs. The D:A:D Study. Signe W. Worm MD, PhD, D:A:D Study Coordinator >

Data Collection on Adverse Events of Anti-HIV Drugs. The D:A:D Study. Signe W. Worm MD, PhD, D:A:D Study Coordinator > Data Collection on Adverse Events of Anti-HIV Drugs The D:A:D Study Signe W. Worm MD, PhD, D:A:D Study Coordinator 2005 -> Background Combination ART (cart) widely introduced in the Europe in 1996 cart

More information

Disclosures. Disclosures. Disclosures. Disclosures. Outline 12/12/2018. Acute Coronary Syndrome in Octogenarians. Off label uses

Disclosures. Disclosures. Disclosures. Disclosures. Outline 12/12/2018. Acute Coronary Syndrome in Octogenarians. Off label uses Acute Coronary Syndrome in Octogenarians Austin Smith, M.D. Adjoint Assistant Professor of Emergency Medicine Department of Emergency Medicine Vanderbilt University School of Medicine Nashville, TN Disclosures

More information

Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor

Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor Leonardo Bolognese Cardiovascular Department, Arezzo, Italy Platelet Reactivity in Patients with STEMI Undergoing Primary PCI Campo G et

More information

Registry Assessment of Peripheral Interventional Devices (RAPID)

Registry Assessment of Peripheral Interventional Devices (RAPID) Registry Assessment of Peripheral Interventional Devices (RAPID) Adding Data Sources May 2, 2018 W. Schuyler Jones, MD Duke Clinical Research Institute Duke Heart Center Disclosures Research Grants: Agency

More information

Mark C. Bieniarz, MD Andrew Harrell, MD Peter Berger, MD

Mark C. Bieniarz, MD Andrew Harrell, MD Peter Berger, MD Mark C. Bieniarz, MD Andrew Harrell, MD Peter Berger, MD Should PCI center activate the cathlab off EMS field interpretation of ECG? Is this happening consistently in New Mexico? What is acceptable rate

More information

Regional STEMI Transfer Systems: the Mayo and NC RACE Experiences

Regional STEMI Transfer Systems: the Mayo and NC RACE Experiences Regional STEMI Transfer Systems: the Mayo and NC RACE Experiences Dr. Henry H. Ting, Mayo Clinic College of Medicine Dr. James G. Jollis,, Duke University Medical Center Mayo Clinic STEMI System for Transferred

More information

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST DECLARATION OF CONFLICT OF INTEREST How to manage antiplatelet treatment in patients with diabetes in acute coronary syndrome Lars Wallentin Professor of Cardiology, Chief Researcher Cardiovascular Science

More information

High-Sensitivity Cardiac Troponin in Suspected ACS

High-Sensitivity Cardiac Troponin in Suspected ACS 15 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes STATE-OF-THE-ART High-Sensitivity Cardiac Troponin in Suspected ACS David A. Morrow, MD, MPH Director, Levine Cardiac Intensive Care

More information

Peri-operative Troponin Measurements - Pathophysiology and Prognosis

Peri-operative Troponin Measurements - Pathophysiology and Prognosis Peri-operative Troponin Measurements - Pathophysiology and Prognosis Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory

More information

Bayer s Xarelto (Rivaroxaban) Meets Primary Efficacy Endpoint and Shows Significant Reduction in Mortality in Major ACS Study

Bayer s Xarelto (Rivaroxaban) Meets Primary Efficacy Endpoint and Shows Significant Reduction in Mortality in Major ACS Study Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Secondary Prevention of Acute Coronary Syndrome (ACS): Bayer s Xarelto (Rivaroxaban)

More information

Li J, Li X, Ross JS, Wang Q, Wang Y, Desai NR, Xu X, Nuti SV, Masoudi FA, Spertus JA, Krumholz HM, Jiang L; China PEACE Collaborative Group.

Li J, Li X, Ross JS, Wang Q, Wang Y, Desai NR, Xu X, Nuti SV, Masoudi FA, Spertus JA, Krumholz HM, Jiang L; China PEACE Collaborative Group. Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI study. Li J, Li X, Ross JS, Wang Q, Wang Y, Desai NR,

More information

Right Care Initiative

Right Care Initiative Right Care Initiative Clinical Quality Improvement Leadership Collaborative Los Angeles CVD HOT SPOT: Heart Disease and Stroke Spreading Evidence-based Strategies to Reduce Premature Disability and Death

More information

CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)

CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) William B. White, MD, for the CARES Investigators Calhoun Cardiology Center University

More information

Recent Victories ALASKA Anchorage Juneau FY (Key Focus Areas) Western States Affiliate Public Policy Priorities

Recent Victories ALASKA Anchorage Juneau FY (Key Focus Areas) Western States Affiliate Public Policy Priorities PE Standards (FY 09-10) $2.21 (Bethel, AK) Local Tobacco Tax Increase (FY 10-11) $1 million in Obesity Program Funding (FY 2012-2013) Pulse Oximetry (FY 2012-2013) $399,000 in Obesity Program Funding (FY

More information

Slide 1. Slide 2. Slide 3. Managing Acute Heart Failure Trials and Tribulations. Declaration of

Slide 1. Slide 2. Slide 3. Managing Acute Heart Failure Trials and Tribulations. Declaration of Slide 1 Managing Acute Heart Failure Trials and Tribulations Martin R Cowie MD MSc FRCP FRCP (Ed) FESC Professor of Cardiology, Imperial College London m.cowie@imperial.ac.uk @ProfMartinCowie Slide 2 Declaration

More information

Central pressures and prediction of cardiovascular events in erectile dysfunction patients

Central pressures and prediction of cardiovascular events in erectile dysfunction patients Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,

More information

How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting

How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting Ahmed A A Suliman, MBBS, FACP, FESC Associate Professor, University of Khartoum Interventional Cardiologist,

More information

DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN

DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN Objectives Gain competence in evaluating chest pain Recognize features of moderate risk unstable angina Review initial management of UA and

More information

ACUTE CORONARY SYNDROME PCI IN THE ELDERLY

ACUTE CORONARY SYNDROME PCI IN THE ELDERLY ACUTE CORONARY SYNDROME PCI IN THE ELDERLY G.KARABELA MD.PhD ATHENS NAVAL HOSPITAL INTERVENTIONAL CARDIOLOGY DEPARTMENT NO CONFLICT OF INTEREST TO DECLAIRE Risk stratification in Αcute Coronary Syndrome.

More information

C. Michael Wright, MD FACC DABCL_FNLA Biography March 2017

C. Michael Wright, MD FACC DABCL_FNLA Biography March 2017 C. Michael Wright, MD FACC DABCL_FNLA Biography March 2017 Address 13090 Caminito del Rocio Del Mar, CA 92014 Cell Phone 858-699-1958 Email cmichael.wright@gmail.com DEA FW3193113 California Medical License

More information

BERKELEY DAVIS IRVINE LOS ANGELES MERCED RIVERSIDE SAN DIEGO SAN FRANCISCO

BERKELEY DAVIS IRVINE LOS ANGELES MERCED RIVERSIDE SAN DIEGO SAN FRANCISCO UNIVERSITY OF CALIFORNIA SAN FRANCISCO BERKELEY DAVIS IRVINE LOS ANGELES MERCED RIVERSIDE SAN DIEGO SAN FRANCISCO SANTA BARBARA SANTA CRUZ STANTON A. GLANTZ, PhD 530 Parnassus Suite 366 Professor of Medicine

More information

ANIL K. CHAGARLAMUDI, M.D. CURRICULUM VITAE

ANIL K. CHAGARLAMUDI, M.D. CURRICULUM VITAE ANIL K. CHAGARLAMUDI, M.D. CURRICULUM VITAE PERSONAL DATA: DATE OF BIRTH: April 23, 1959 PLACE OF BIRTH: Amalapuam, A.P., India EDUCATION: COLLEGE: Andhra Christian College BS Degree Andhra Loyola College

More information

Prospective Validation of a Clinical Decision Rule to Identify ED Chest Pain Patients Who Can Safely be Removed from Cardiac Monitoring

Prospective Validation of a Clinical Decision Rule to Identify ED Chest Pain Patients Who Can Safely be Removed from Cardiac Monitoring Prospective Validation of a Clinical Decision Rule to Identify ED Chest Pain Patients Who Can Safely be Removed from Cardiac Monitoring Department of Emergency Medicine CAEP 2015 Shahbaz Syed PGY 3 FRCP

More information

Exhibit EP16.h University of Virginia Medical Center Clinical Decision Tool

Exhibit EP16.h University of Virginia Medical Center Clinical Decision Tool TITLE: Emergency Management for Suspicion of Cardiac Event PURPOSE: Increasingly, patients have multiple morbidities and are at risk of adverse events related or unrelated to the condition for which they

More information

CENTRALIZED FELLOWSHIP PROGRAM COORDINATION

CENTRALIZED FELLOWSHIP PROGRAM COORDINATION CENTRALIZED FELLOWSHIP PROGRAM COORDINATION A Win-Win (and a Few Challenges!) Affiliation Lisa Brath, MD Director, Pulmonary Critical Care Medicine Fellowship Training Program Stephanie Call, MD, MSPH

More information

Heart Rate in Patients with Coronary Artery Disease - the Lower the Better? An Analysis from the Treating to New Targets (TNT) trial

Heart Rate in Patients with Coronary Artery Disease - the Lower the Better? An Analysis from the Treating to New Targets (TNT) trial Heart Rate in Patients with Coronary Artery Disease - the Lower the Better? An Analysis from the Treating to New Targets (TNT) trial Sripal Bangalore, MD, MHA, Chuan-Chuan Wun, PhD, David A DeMicco, PharmD,

More information

Exercise treadmill testing is frequently used in clinical practice to

Exercise treadmill testing is frequently used in clinical practice to Preventive Cardiology FEATURE Case Report 55 Commentary 59 Exercise capacity on treadmill predicts future cardiac events Pamela N. Peterson, MD, MSPH 1-3 David J. Magid, MD, MPH 3 P. Michael Ho, MD, PhD

More information

Menopausal hormone therapy currently has no evidence-based role for

Menopausal hormone therapy currently has no evidence-based role for IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),

More information

Recommendations for criteria for STEMI systems of care: A focus on pharmacoinvasive strategies

Recommendations for criteria for STEMI systems of care: A focus on pharmacoinvasive strategies Recommendations for criteria for STEMI systems of care: A focus on pharmacoinvasive strategies Mohammad Zubaid, MB, ChB, FRCPC, FACC Professor of Medicine, Kuwait University Chairman, Faculty of Cardiology,

More information

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study Tracy Y. Wang, MD, MHS, MSc, FACC, FAHA presenting on behalf of ARTEMIS Investigators Guidelines DAPT

More information

Indications for sublobar resection for localized NSCLC

Indications for sublobar resection for localized NSCLC Indications for sublobar resection for localized NSCLC David H Harpole Jr, MD Professor of Surgery Associate Professor in Pathology Vice Chief, Division of Surgical Services Duke University School of Medicine

More information

Is it safe to discharge patients 24 hours after uncomplicated successful primary percutaneous coronary intervention

Is it safe to discharge patients 24 hours after uncomplicated successful primary percutaneous coronary intervention Is it safe to discharge patients 24 hours after uncomplicated successful primary percutaneous coronary intervention DA Jones, J Howard, S Gallagher, KS Rathod, A Jain, S Mohiddin, C Knight, A Mathur, EJ

More information

Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials

Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La

More information

The Strategic Reperfusion Early After STEMI study Implications for clinical practice

The Strategic Reperfusion Early After STEMI study Implications for clinical practice The Strategic Reperfusion Early After STEMI study Implications for clinical practice Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization and Interventional

More information

INSIGHTS AND BEST PRACTICES FOR EMS AGENCIES

INSIGHTS AND BEST PRACTICES FOR EMS AGENCIES 2018 ESO EMS INDEX: INSIGHTS AND BEST PRACTICES FOR EMS AGENCIES AUTHORS DR. BRENT MYERS, CHIEF MEDICAL OFFICER, ESO ALLEN JOHNSON, VICE PRESIDENT FOR HEALTH DATA EXCHANGE, ESO CONTEXT AND OVERVIEW FOR

More information

Welcome Please stand by. We will begin shortly.

Welcome Please stand by. We will begin shortly. Welcome Please stand by. We will begin shortly. SCLC and Pfizer IGLC 2015 Grantees Forum Call Wednesday, December 9, 2015 2pm ET (60 minutes) Moderator Catherine Saucedo Deputy Director, Smoking Cessation

More information

Risk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium

Risk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium Risk Stratification of ACS Patients Frans Van de Werf, MD, PhD University of Leuven, Belgium Which type of ACS patients are we talking about to day? 4/14/2011 STEMI and NSTEMI in the NRMI registry from

More information

A. Personal Statement

A. Personal Statement BIOGRAPHICAL SKETCH Provide the following information for the Senior/key personnel and other significant contributors. Follow this format for each person. DO NOT EXCEED FIVE PAGES. NAME: Norman L. Foster

More information

ACCP Cardiology PRN Journal Club

ACCP Cardiology PRN Journal Club ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy

More information

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease D. Dallmeier 1, D. Rothenbacher 2, W. Koenig 1, H. Brenner

More information

Intermountain Medical Center Murray, Utah Friday, January 23, Course Director: Kevin A. Walker, MD

Intermountain Medical Center Murray, Utah Friday, January 23, Course Director: Kevin A. Walker, MD 5 th Annual Utah Sleep Society Conference Intermountain Medical Center Murray, Utah Friday, January 23, 2015 Course Director: Kevin A. Walker, MD Purpose This educational activity will provide an opportunity

More information

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham Chest pain and troponins on the acute take J N Townend Queen Elizabeth Hospital Birmingham 3 rd Universal Definition of Myocardial Infarction Type 1: Spontaneous MI related to atherosclerotic plaque rupture

More information

THE BRIDGE-ACS TRIAL

THE BRIDGE-ACS TRIAL A Multifaceted Intervention to Narrow the Evidence-Based Gap in the Treatment of Acute Coronary Syndromes: THE BRIDGE-ACS TRIAL Presenter: Otavio Berwanger (MD; PhD) on Behalf of the BRIDGE-ACS Steering

More information

10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice

10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice 10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice Ajar Kochar, MD on behalf of: Anita Y. Chen, Puza P. Sharma, Neha J. Pagidipati, Gregg C. Fonarow, Patricia

More information

Is the combination of antithrombotics and lowdose anticoagulants worthwhile in PAD The VOYAGER trial

Is the combination of antithrombotics and lowdose anticoagulants worthwhile in PAD The VOYAGER trial Is the combination of antithrombotics and lowdose anticoagulants worthwhile in PAD The VOYAGER trial Thomas HW Stadlbauer Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar, Technical

More information

8 th ANNUAL CLINICAL CARDIOLOGY COURSE Nashville, TN

8 th ANNUAL CLINICAL CARDIOLOGY COURSE Nashville, TN 8 th ANNUAL CLINICAL CARDIOLOGY COURSE Nashville, TN Mark your Calendar for July 26-29, 2018 to Attend the Only Available Comprehensive Review of Clinical Cardiology Practice designed for Nurse Practitioners

More information

credo: Why, What and How Laura Lee Hall, Ph.D. Associate Director, Strategic Educational Initiatives American College of Cardiology

credo: Why, What and How Laura Lee Hall, Ph.D. Associate Director, Strategic Educational Initiatives American College of Cardiology credo: Why, What and How Laura Lee Hall, Ph.D. Associate Director, Strategic Educational Initiatives American College of Cardiology National Minority Quality Forum Washington, DC April 19 th, 2010 Disclosures

More information

Cancer Care in the Veterans Health Administration

Cancer Care in the Veterans Health Administration Cancer Care in the Veterans Health Administration Michael J Kelley, MD National Program Director for Oncology Department of Veterans Affairs Professor of Medicine Duke University Medical Center Chief,

More information

HYPERTENSION: UPDATE 2018

HYPERTENSION: UPDATE 2018 HYPERTENSION: UPDATE 2018 From the Cardiologist point of view Richard C Padgett, MD I have no disclosures HYPERTENSION ALWAYS THE ELEPHANT IN THE EXAM ROOM BUT SOMETIMES IT CHARGES HTN IN US ~78 million

More information

Clopidogrel and Aspirin in Acute Ischemic Stroke and TIA: Final Results of the POINT Trial

Clopidogrel and Aspirin in Acute Ischemic Stroke and TIA: Final Results of the POINT Trial Clopidogrel and Aspirin in Acute Ischemic Stroke and TIA: Final Results of the POINT Trial S. Claiborne Johnston, 1 J. Donald Easton, 2 Mary Farrant, 2 William Barsan, 3 Robin A. Conwit, 4 Jordan J. Elm,

More information

venous thromboembolism

venous thromboembolism Venous thromboembolism reduction initiative: A multifaceted collaborative effort to protect Intermountain Healthcare patients from hospitalassociated venous thromboembolism (HA-VTE) 14 th Annual Research

More information

A Randomized Trial of a Multivitamin (MVM) in the Prevention of Cardiovascular Disease in Men: The Physicians Health Study (PHS) II

A Randomized Trial of a Multivitamin (MVM) in the Prevention of Cardiovascular Disease in Men: The Physicians Health Study (PHS) II A Randomized Trial of a Multivitamin (MVM) in the Prevention of Cardiovascular Disease in Men: The Physicians Health Study (PHS) II Presenter Disclosure Information Howard D. Sesso, ScD, MPH Relevant Disclosures:

More information